 - CrCl 50mLmin per Cockcroft-Gault Prior anti-cancer treatment related toxicities except alopecia and lab values as outlined in the criterion above must be less than or equal to Grade 1 as per CTCAEv4 Willing to undergo biopsy for research purposes only Females of child-bearing potential: willing to use two forms of effective contraception, and to continue use for 16 weeks post last dose of study medication. Effective contraception is defined as any medically recommended method or combination of methods as per standard of care, including abstinence. Females of non-childbearing potential are those who are postmenopausal defined as greater than 1 year without menses with appropriate clinical profile, e.g., age appropriate: 45 years in the absence of hormone replacement therapy HRT. In questionable cases, the subject must have a follicle stimulating hormone FSH value 40 mIUmL and an estradiol value 40pgmL 140 pmolL; or who have had a bilateral tubal ligation or tubal occlusion, bilateral oophorectomy, or hysterectomy. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described from D1 of treatment, throughout the treatment period, and for 16 weeks after the last dose of study treatment. If a subject becomes pregnant during the treatment period of the study, the study treatments should be stopped immediately. 